Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

By LabMedica International staff writers
Posted on 22 Jul 2014
A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.

Investigators at Rush University (Chicago, IL, USA) have been exploring the novel use of cinnamon in upregulating the enzymes Parkin and DJ-1 and protecting dopaminergic neurons in the MPTP mouse model of PD. More...
Recently they found that oral feeding of cinnamon (Cinnamonum verum) powder produced sodium benzoate (NaB) in the blood and brains of the mice.

Parkin is a protein which in humans is encoded by the PARK2 gene. The precise function of this protein is unknown; however, the protein is a component of a multiprotein E3 ubiquitin ligase complex which in turn is part of the ubiquitin-proteasome system that mediates the targeting of proteins for degradation. Mutations in this gene are known to cause a familial form of Parkinson's disease known as autosomal recessive juvenile Parkinson's disease (AR-JP). How loss of function of the parkin protein leads to dopaminergic cell death in this disease is unclear. The prevailing hypothesis is that parkin helps degrade one or more proteins toxic to dopaminergic neurons.

DJ-1 is a protein which in humans is encoded by the PARK7 gene. DJ-1 belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death.

In the current study, which was published in the June 20, 2014, online edition of the Journal of Neuroimmune Pharmacology, the investigators found that the proinflammatory cytokine IL-1beta decreased the level of Parkin/DJ-1 in mouse astrocytes. However, the cinnamon metabolite NaB abrogated IL-1beta-induced loss of these proteins. These findings at the molecular level paralleled improved clinical appearance of the PD mice following cinnamon feeding.

“Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of PD,” said senior author Dr. Kalipada Pahan, professor of neurology at Rush University. “It is known that some important proteins like Parkin and DJ-1 decrease in the brain of PD patients.”

“Cinnamon is metabolized in the liver to sodium benzoate, which is an FDA-approved drug used in the treatment for hepatic metabolic defects associated with hyperammonemia,” said Dr. Pahan. “Cinnamon has been used widely as a spice throughout the world for centuries and is also widely used as a food preservative due to its microbiocidal effect. This could potentially be one of the safest approaches to halt disease progression in Parkinson’s patients.”


Related Links:
Rush University



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Multi-Chamber Washer-Disinfector
WD 390
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.